Data Sheet (Cat.No.T2546)

TargetMol

Pimozide

Chemical Properties



CAS No. : 2062-78-4

Formula: C28H29F2N3O

Molecular Weight: 461.55

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Pimozide (R6238) is a diphenylbutylpiperidine derivative and a dopamine antagonist with the antipsychotic property. Pimozide selectively inhibits type 2 dopaminergic receptors in the central nervous system (CNS), thereby decreasing dopamine neurotransmission and reducing the occurrence of the motor and vocal tics and delusions of parasitosis. In addition, this agent antagonizes alpha-adrenergic and 5-HT2 receptors.
Targets(IC50)	Adrenergic Receptor,STAT,Parasite,Dopamine Receptor,Potassium Channel

Solubility Information

Solubility	DMSO: 41 mg/mL (88.83 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.17 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1666 mL	10.8331 mL	21.6661 mL
5 mM	0.4333 mL	2.1666 mL	4.3332 mL
10 mM	0.2167 mL	1.0833 mL	2.1666 mL
50 mM	0.0433 mL	0.2167 mL	0.4333 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Silva MR, et al. Pharmacol Toxicol. 2003 Jul;93(1):42-7.

Wang Y, Wang X, Wang K, et al.Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop.Journal of Experimental & Clinical Cancer Research.2023, 42(1): 1-17.